Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat plus bortezomib dose-escalation study in relapsed multiple myeloma
2006-006638-16Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat and bortezomib in multiple myeloma (MM), sponsored by Novartis. Primary endpoint: Dose-limiting toxicity incidence. Started Jul 2007; status: completed.
02
Drugs
panobinostatbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-006638-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006638-16.